Azitra Inc(AZTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AZTR Azitra Inc

Trading 03-16 11:55:12 EDT

0.1582

-0.0128

-7.49%

High0.1650	Low0.1540	Vol374.65K
Open0.1606	D1 Closing0.1710	Amplitude6.43%
Mkt Cap2.56M	Tradable Cap2.56M	Total Shares16.19M
T/O59.17K	T/O Rate2.32%	Tradable Shares16.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AZTR","market":"US","secType":"STK","nameCN":"Azitra Inc","latestPrice":0.1582,"timestamp":1773676388983,"preClose":0.171,"halted":0,"volume":374652,"delay":0,"changeRate":-0.07485380116959067,"floatShares":16181700,"shares":16192438,"eps":-2.25,"marketStatus":"Trading","change":-0.0128,"latestTime":"03-16 11:55:12 EDT","open":0.1606,"high":0.165,"low":0.154,"amount":59172.13600236,"amplitude":0.064327,"askPrice":0.1583,"askSize":100,"bidPrice":0.1544,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-2.25,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773691200000},"marketStatusCode":2,"adr":0,"listingDate":1684382400000,"exchange":"AMEX","adjPreClose":0.171,"preHourTrading":{"tag":"盘前","latestPrice":0.1625,"preClose":0.171,"latestTime":"09:26 EDT","volume":32308,"amount":5150.66703812,"timestamp":1773667616400,"change":-0.0085,"changeRate":-0.049708,"amplitude":0.038012},"postHourTrading":{"tag":"盘后","latestPrice":0.154,"preClose":0.171,"latestTime":"19:56 EDT","volume":184521,"amount":28320.731058,"timestamp":1773446176764,"change":-0.017,"changeRate":-0.099415,"amplitude":0.152047},"volumeRatio":0.41561},"requestUrl":"/m/hq/s/AZTR","defaultTab":"news","newsList":[{"id":"2619143981","title":"Azitra Receives Notice of Non-Compliance From Nyse American and Makes Nyse American Section 610(B) Public Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2619143981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619143981?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:17","pubTimestamp":1773436647,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4010LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2619143624","title":"Azitra Receives NYSE American Non-Compliance Notice on Stockholders’ Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2619143624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619143624?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:15","pubTimestamp":1773436512,"startTime":"0","endTime":"0","summary":"Azitra Inc. said it received a notice of non-compliance from NYSE American for failing to meet continued listing standards tied to minimum stockholders’ equity under Sections 1003 and 1003 of the NYSE American Company Guide. The company has until April 1, 2027 to regain compliance under an accepted remediation plan, and faces potential delisting proceedings if it does not make sufficient progress. Azitra also noted its latest annual report included an auditor “going concern” paragraph, which it disclosed publicly under NYSE American Sections 410 and 610.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5gCzQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2617579559","title":"Azitra Delays Shareholder Meeting to March 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579559?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:30","pubTimestamp":1772746227,"startTime":"0","endTime":"0","summary":"Azitra Inc. said it has canceled its special meeting of stockholders that had been scheduled for Feb. 6, 2026 and was later adjourned to March 6, 2026 due to a lack of quorum. The company announced the cancellation on March 5, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLydp6v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2614189892","title":"Anitra Q4 EPS $(0.81) Misses $(0.33) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614189892","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614189892?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:38","pubTimestamp":1772231929,"startTime":"0","endTime":"0","summary":"Anitra (AMEX:AZTR) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.33) by 149.23 percent. This is a 61.06 percent increase over losses of $(2.08) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50949678/anitra-q4-eps-0-81-misses-0-33-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Anitra Q4 EPS $(0.81) Misses $(0.33) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2614898686","title":"Press Release: Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2614898686","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614898686?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:30","pubTimestamp":1772231400,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc.  , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update.-- Initiated Phase 1/2 Trial for ATR-04 program targeting oncology patients. with EGFRi-associated rash; presented ATR-04 trial design and update at. -- Announced positive preclinical data for ATR-01 program, targeting the. Mr. Salva continued: \"Also in 2025, we presented positive preclinical data for our ATR-01 program targeting ichthyosis vulgaris. Impacting approximately 1.3 million in the United States with no treatment options beyond symptom management, ichthyosis vulgaris, is an autosomal semidominant genetic disorder caused by missing or abnormal filaggrin levels. The condition is characterized by generalized xerosis and fine, white to gray scales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2614609438","title":"Azitra posts FY 2025 net loss of USD 11.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614609438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614609438?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:03","pubTimestamp":1772229821,"startTime":"0","endTime":"0","summary":"Azitra reported a FY 2025 net loss of USD 11.0 million, with R&D expenses of USD 4.8 million and G&A expenses of USD 6.2 million. Cash and cash equivalents were USD 2.1 million as of December 31, 2025. During FY 2025, Azitra initiated a Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash and dosed the first patient in Q3 2025; topline data from the first cohort is expected around mid-2026. For its lead program ATR-12  in Netherton syndrome, the company reported promising safety data in June 2025 with 50% of patients enrolled, and said topline Phase 1b data are anticipated in H2 2026. Azitra also announced positive preclinical data for ATR-01 in ichthyosis vulgaris in Q3 2025 and said IND-enabling studies will continue in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL8S2lPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2614860947","title":"Azitra FY 2025 net loss attributable to common shareholders widens 22% to USD 11.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614860947","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614860947?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:03","pubTimestamp":1772229800,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDLnRqBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2613711139","title":"Azitra Adds MD Anderson Cancer Center as ATR-04 Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711139","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613711139?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:01","pubTimestamp":1771938092,"startTime":"0","endTime":"0","summary":"Azitra Inc. has added The University of Texas MD Anderson Cancer Center as a new clinical site for its ongoing Phase 1/2 trial of ATR-04, a topical live biotherapeutic being evaluated for EGFR inhibitor-associated skin rash. The expansion is intended to broaden the study’s footprint and potentially speed patient enrollment and treatment milestones.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLbSdPPh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2613657711","title":"Azitra, Inc. Announces Addition of Md Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of Atr-04 Targeting Egfri-Associated Skin Rash","url":"https://stock-news.laohu8.com/highlight/detail?id=2613657711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613657711?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA6SGMGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2612407074","title":"Azitra to Present at BIO Investment & Growth Summit in Miami Beach","url":"https://stock-news.laohu8.com/highlight/detail?id=2612407074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612407074?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:02","pubTimestamp":1771506143,"startTime":"0","endTime":"0","summary":"Azitra to Present at BIO Investment & Growth Summit in Miami Beach               Azitra, Inc. will present at the BIO Investment & Growth Summit in Miami Beach, Florida on March 2, 2026 (2:15 PM ET) a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLccYG6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2609511628","title":"Azitra Inc. to Hold Reconvened Special Meeting on March 6, 2026, to Vote on Proxy Proposals After Previous Lack of Quorum","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511628?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:15","pubTimestamp":1770412519,"startTime":"0","endTime":"0","summary":"Azitra Inc. will hold a reconvened Special Meeting of shareholders on March 6, 2026, to vote on a proposal to adjourn the meeting if necessary in order to solicit additional proxies if there are insufficient votes in favor of the main proposal. The company's Board of Directors and management recommend that shareholders vote in favor of the proposal. Shareholders of record as of January 2, 2026, are encouraged to vote their shares before the deadline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL1NPMR7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2601031328","title":"Azitra Inc. to Present Clinical Strategy at Biotech Showcase in San Francisco","url":"https://stock-news.laohu8.com/highlight/detail?id=2601031328","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601031328?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790916,"startTime":"0","endTime":"0","summary":"Azitra Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, will present at the Biotech Showcase 2026 in San Francisco. The event is scheduled for Tuesday, January 13, 2026, at 2:30 PM PT, and will take place at the Hilton San Francisco Union Square, Yosemite C . Travis Whitfill, Chief Operating Officer, will represent the company, highlighting Azitra's clinical development strategy, recent achievements, and upcoming milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLPB4Mn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2593448091","title":"Azitra Inc. Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448091?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:06","pubTimestamp":1766523997,"startTime":"0","endTime":"0","summary":"Azitra Inc. has scheduled a Special Meeting of Stockholders to be held virtually on February 6, 2026. The meeting will be conducted exclusively via a live audio webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL3C49Jh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZTR","BK4139"],"gpt_icon":0},{"id":"2592152943","title":"BRIEF-Azitra Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE American","url":"https://stock-news.laohu8.com/highlight/detail?id=2592152943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592152943?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:11","pubTimestamp":1766005883,"startTime":"0","endTime":"0","summary":"BRIEF-Azitra Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE AmericanDec 17 (Reuters) - Azitra Inc AZTR.A:AZITRA RECEIVES NOTICE OF ACCEPTANCE OF THE LISTING STANDARDS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5XS2TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2592943188","title":"Azitra Faces NYSE American Listing Compliance Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943188","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943188?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:10","pubTimestamp":1766005814,"startTime":"0","endTime":"0","summary":"Azitra Inc. has received notice from NYSE American LLC that it was not in compliance with the minimum stockholders' equity requirement under Section 1003 of the NYSE American Company Guide, which mandates stockholders' equity of $4.0 million or more for companies with reported losses in three of the four most recent fiscal years. The Exchange has approved Azitra's plan to regain compliance with these continued listing standards. The company has also noted potential risks related to regulatory approval delays and changes in the regulatory framework that could affect its operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on December 17, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9YMF03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0980610538.SGD","LU0154236417.USD","LU0738911758.USD","LU0689626769.HKD","LU0130102774.USD","BK4588","LU0661504455.SGD","LU2237957902.USD","LU0256863902.USD","LU1974910355.USD","IE00BQXX3C00.GBP","LU0949170772.SGD","LU2237957811.SGD","BK4139","LU1153585028.USD","LU0072461881.USD","LU0154245673.USD","LU1201861249.SGD","LU0971096721.USD","BK4112","LU0256863811.USD","LU0417517546.SGD","LU1506573853.SGD","LU1917777945.USD","LU2023250504.SGD","LU0011850046.USD","LU0648001328.SGD","ICE","LU0162691827.USD","LU0477156953.USD","LU0124676726.USD","IE00BQXX3D17.EUR","BK4585","LU2106854487.HKD","LU0314106906.USD","LU0154245756.USD","LU0130517989.USD","SG9999004303.SGD","SGXZ23171101.USD","GB00BDT5M118.USD","IE00BQXX3F31.USD","LU1363072403.SGD","LU2023250843.SGD","AZTR","LU0390134368.USD"],"gpt_icon":0},{"id":"2592439229","title":"Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan From Nyse American","url":"https://stock-news.laohu8.com/highlight/detail?id=2592439229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592439229?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:10","pubTimestamp":1766005800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5XS2TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2586399402","title":"Azitra Inc Secures $1.5M in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2586399402","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586399402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:24","pubTimestamp":1764109499,"startTime":"0","endTime":"0","summary":"An announcement from Azitra Inc ( ($AZTR) ) is now available. On November 24, 2025, Azitra, Inc. entered into a securities purchase agreement with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/azitra-inc-secures-1-5m-in-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/azitra-inc-secures-1-5m-in-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2585467023","title":"Press Release: Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2585467023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585467023?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:00","pubTimestamp":1763992800,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc.  , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,687,500 shares of common stock , together with warrants to purchase up to an aggregate 4,687,500 shares of common stock, in a private placement priced at a premium to market under NYSE rules . The combined effective offering price for each share of common stock  and accompanying warrant is $0.32. The warrants will have an exercise price of $0.32 per share, will be exercisable upon shareholder approval and will expire on the five-year anniversary from such date of shareholder approval.Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designe","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NYSE","AZTR","BK4139"],"gpt_icon":0},{"id":"2583898705","title":"Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583898705","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583898705?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:17","pubTimestamp":1762985867,"startTime":"0","endTime":"0","summary":"Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48821664/anitra-q3-eps-0-67-beats-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AZTR"],"gpt_icon":0},{"id":"2583589386","title":"Press Release: Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589386?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:15","pubTimestamp":1762985700,"startTime":"0","endTime":"0","summary":"BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc.  , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update.-- Dosed first patient in Phase 1/2 trial for ATR-04 program targeting. oncology patients with EGFRi-associated rash in August 2025. -- Presented positive preclinical data at BIO-Europe for ATR-01 program,\"The third quarter of 2025 was an impactful period for Azitra as we continued to progress our live biotherapeutic programs, including dosing the first patient in our Phase 1/2 trial for ATR-04 targeting oncology patients with EGFRi-associated rash,\" said Francisco Salva, CEO of Azitra. \"This candidate previously received Fast Track designation from the FDA as there is an incredible opportunity to help alleviate a major dermatologic toxicity associated with EGFR inhibitor treatments, which impacts approximate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4139","AZTR","R","BK4232"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.azitrainc.com","stockEarnings":[{"period":"1week","weight":-0.0521},{"period":"1month","weight":-0.1659},{"period":"3month","weight":-0.5039},{"period":"6month","weight":-0.7894},{"period":"1year","weight":-0.926},{"period":"ytd","weight":-0.3542}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.","exchange":"AMEX","name":"Azitra Inc","nameEN":"Azitra Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Azitra Inc(AZTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Azitra Inc(AZTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Azitra Inc,AZTR,Azitra Inc股票,Azitra Inc股票老虎,Azitra Inc股票老虎国际,Azitra Inc行情,Azitra Inc股票行情,Azitra Inc股价,Azitra Inc股市,Azitra Inc股票价格,Azitra Inc股票交易,Azitra Inc股票购买,Azitra Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Azitra Inc(AZTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Azitra Inc(AZTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}